bioAffinity Technologies Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company specializing in noninvasive detection of early-stage lung cancer, reported financial results for the quarter ending June 30, 2025. The company achieved a significant 62% increase in CyPath® Lung revenues year-over-year for the first six months of 2025. This surge is attributed to growing clinical adoption and supporting physician-authored case studies that validate the test's effectiveness in identifying early-stage lung cancers. In May 2025, bioAffinity Technologies raised $3.25 million through a public offering. However, cash and cash equivalents decreased to $0.8 million as of June 30, 2025, from $1.1 million at the end of 2024. Additionally, the company reported a 72% increase in completed CyPath® Lung tests in July compared to the previous monthly average for the first half of 2025, setting record monthly sales in both June and July. The company also expanded its intellectual property portfolio with new patent grants in the U.S., China, Canada, and Australia, including a novel U.S. patent for a broad-spectrum cancer therapy. Furthermore, bioAffinity presented research on a siRNA-based cancer therapy at the 2025 RNA Therapeutics Conference, highlighting a promising new approach to selectively target cancer cells. Maria Zannes, President and CEO of bioAffinity Technologies, was appointed to the American Lung Association in Texas Leadership Board, reinforcing the company's commitment to lung health and early cancer detection.